Bristol-Myers Squibb Company (NYSE:BMY) | FDA approves Bristol-Myers drug for rare body fat disorder

February 25, 2014 at 10:34 AM EST

[Reuters] – Bristol-Myers Squibb Co said the U.S. Food and Drug Administration approved its drug to treat rare and potentially fatal disorders involving loss of body fat. The drug has been approved as . . . → Read More: Bristol-Myers Squibb Company (NYSE:BMY) | FDA approves Bristol-Myers drug for rare body fat disorder Similar Articles: Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J, Pharmacyclics drug gets U.S. approval for leukemia Merck & Co. Inc. (NYSE:MRK) – FDA panel says Merck’s allergy drug effective Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol drug for fat disorder may work, but risky -FDA staff

Bristol-Myers Squibb Company (NYSE:BMY) [Reuters] – Bristol-Myers Squibb Co said the U.S. Food and Drug Administration approved its drug to treat rare and potentially fatal disorders involving loss of body fat. The drug has been approved as a replacement therapy to treat complications caused by leptin hormone deficiency in patients with congenital or acquired generalized lipodystrophy. Generalized lipodystrophy patients experience a loss of fat tissue, especially under the skin, leading to low … [visit site to read more]